Hans Herfarth1, Edward L Barnes2, John F Valentine3, John Hanson4, Peter D R Higgins5, Kim L Isaacs2, Susan Jackson2, Mark T Osterman6, Kristen Anton7, Anastasia Ivanova8, Millie D Long2, Christopher Martin9, Robert S Sandler10, Bincy Abraham11, Raymond K Cross12, Gerald Dryden13, Monika Fischer14, William Harlan15, Campbell Levy16, Robert McCabe17, Steven Polyak18, Sumona Saha19, Emmanuelle Williams20, Vijay Yajnik21, Jose Serrano22, Bruce E Sands23, James D Lewis24. 1. Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina; University of North Carolina Multidisciplinary Center for Inflammatory Bowel Diseases, Chapel Hill, North Carolina. Electronic address: hherf@med.unc.edu. 2. Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina; University of North Carolina Multidisciplinary Center for Inflammatory Bowel Diseases, Chapel Hill, North Carolina. 3. Division of Gastroenterology, Hepatology and Nutrition, University of Utah, Salt Lake City, Utah. 4. Atrium Health, Charlotte, North Carolina. 5. Division of Gastroenterology, University of Michigan, Ann Arbor, Michigan. 6. Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. 7. Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina; Center for Gastrointestinal Biology and Disease, University of North Carolina, Chapel Hill, North Carolina; Geisel School of Medicine at Dartmouth, Hanover, New Hampshire. 8. Department of Biostatistics, University of North Carolina, Chapel Hill, North Carolina. 9. Center for Gastrointestinal Biology and Disease, University of North Carolina, Chapel Hill, North Carolina. 10. Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina; Center for Gastrointestinal Biology and Disease, University of North Carolina, Chapel Hill, North Carolina. 11. Division of Gastroenterology and Hepatology, Houston Methodist-Weill Cornell, Houston, Texas. 12. Division of Gastroenterology and Hepatology, University of Maryland School of Medicine, Baltimore, Maryland. 13. Division of Gastroenterology, Hepatology and Nutrition, University of Louisville, Louisville, Kentucky. 14. Division of Gastroenterology and Hepatology, Indiana University, Indianapolis, Indiana. 15. Asheville Gastroenterology Associates, Asheville, North Carolina. 16. Section of Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire. 17. Minnesota Gastroenterology, Plymouth, Minnesota. 18. Division of Gastroenterology, Hepatology and Nutrition, University of Iowa, Iowa City, Iowa. 19. Division of Gastroenterology and Hepatology, University of Wisconsin, Madison, Wisconsin. 20. Division of Gastroenterology and Hepatology, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania. 21. Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 22. Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland. 23. Dr Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York. 24. Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
Abstract
BACKGROUND & AIMS:Parenteral methotrexate induces clinical remission but not endoscopic improvement of mucosal inflammation in patients with ulcerative colitis (UC). We performed a randomized, placebo-controlled trial to assess the efficacy of parenteral methotrexate in maintaining steroid-free response or remission in patients with UC after induction therapy withmethotrexate and steroids. METHODS: We performed a 48-week trial, from February 2012 through May 2016, of 179 patients with active UC (Mayo score of 6-12 with endoscopy subscore ≥ 2) despite previous conventional or biological therapy. The study comprised a 16-week open label methotrexate induction period followed by a 32-week double-blind, placebo-controlled maintenance period. Patients were given subcutaneous methotrexate (25 mg/wk) and a 12-week steroid taper. At week 16, steroid-free responders were randomly assigned to groups that either continued methotrexate (25 mg/wk, n = 44) or were given placebo (n = 40) until week 48. We compared the efficacy of treatment by analyzing the proportion of patients who remained relapse free and were in remission at week 48 without use of steroids or other medications to control disease activity. RESULTS:Ninety-one patients (51%) achieved response at week 16, and 84 patients were included in the maintenance period study. During this period, 60% of patients in the placebo group (24/40) and 66% in the methotrexate group (29/44) had a relapse of UC (P = .75). At week 48, 30% of patients in the placebo group (12/40) and 27% of patients in the methotrexate group (12/44) were in steroid-free clinical remission without need for additional therapies (P = .86). No new safety signals for methotrexate were detected. CONCLUSIONS:Parenteral methotrexate (25 mg/wk) was not superior to placebo in preventing relapses of UC in patients who achieved steroid-free response during induction therapy. ClinicalTrials.gov, Number: NCT01393405.
RCT Entities:
BACKGROUND & AIMS: Parenteral methotrexate induces clinical remission but not endoscopic improvement of mucosal inflammation in patients with ulcerative colitis (UC). We performed a randomized, placebo-controlled trial to assess the efficacy of parenteral methotrexate in maintaining steroid-free response or remission in patients with UC after induction therapy with methotrexate and steroids. METHODS: We performed a 48-week trial, from February 2012 through May 2016, of 179 patients with active UC (Mayo score of 6-12 with endoscopy subscore ≥ 2) despite previous conventional or biological therapy. The study comprised a 16-week open label methotrexate induction period followed by a 32-week double-blind, placebo-controlled maintenance period. Patients were given subcutaneous methotrexate (25 mg/wk) and a 12-week steroid taper. At week 16, steroid-free responders were randomly assigned to groups that either continued methotrexate (25 mg/wk, n = 44) or were given placebo (n = 40) until week 48. We compared the efficacy of treatment by analyzing the proportion of patients who remained relapse free and were in remission at week 48 without use of steroids or other medications to control disease activity. RESULTS: Ninety-one patients (51%) achieved response at week 16, and 84 patients were included in the maintenance period study. During this period, 60% of patients in the placebo group (24/40) and 66% in the methotrexate group (29/44) had a relapse of UC (P = .75). At week 48, 30% of patients in the placebo group (12/40) and 27% of patients in the methotrexate group (12/44) were in steroid-free clinical remission without need for additional therapies (P = .86). No new safety signals for methotrexate were detected. CONCLUSIONS: Parenteral methotrexate (25 mg/wk) was not superior to placebo in preventing relapses of UC in patients who achieved steroid-free response during induction therapy. ClinicalTrials.gov, Number: NCT01393405.
Authors: B G Feagan; R N Fedorak; E J Irvine; G Wild; L Sutherland; A H Steinhart; G R Greenberg; J Koval; C J Wong; M Hopkins; S B Hanauer; J W McDonald Journal: N Engl J Med Date: 2000-06-01 Impact factor: 91.245
Authors: Brian Bressler; John K Marshall; Charles N Bernstein; Alain Bitton; Jennifer Jones; Grigorios I Leontiadis; Remo Panaccione; A Hillary Steinhart; Francis Tse; Brian Feagan Journal: Gastroenterology Date: 2015-03-04 Impact factor: 22.682
Authors: Remo Panaccione; Subrata Ghosh; Stephen Middleton; Juan R Márquez; Boyd B Scott; Laurence Flint; Hubert J F van Hoogstraten; Annie C Chen; Hanzhe Zheng; Silvio Danese; Paul Rutgeerts Journal: Gastroenterology Date: 2014-02 Impact factor: 22.682
Authors: B Jharap; W J Sandborn; W Reinisch; G D'Haens; A M Robinson; W Wang; B Huang; A Lazar; R B Thakkar; J-F Colombel Journal: Aliment Pharmacol Ther Date: 2015-09-03 Impact factor: 8.171
Authors: Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne Journal: Gut Date: 2019-09-27 Impact factor: 23.059
Authors: Frank I Scott; Michelle Luo; Yash Shah; Karen Lasch; Ravy K Vajravelu; Ronac Mamtani; Blair Fennimore; Mark E Gerich; James D Lewis Journal: J Crohns Colitis Date: 2020-06-19 Impact factor: 9.071
Authors: Ryan Morrow; Ryan Funk; Mara Becker; Ashley Sherman; Leon Van Haandel; Taina Hudson; Rebecca Casini; Valentina Shakhnovich Journal: Pharmaceuticals (Basel) Date: 2021-05-14